MEDICAL NEWS HEADLINE:
NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO)
TO CANCER CELL SITES
PATENT ISSUED IN THE TRANSPORT OF NO MOLECULE, L-ARGININE
MEDICAL NEWS HEADLINE:
NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER
In the treatment of cancer, there has been a great deal of
interest in developing techniques that are capable of opening
the blood-brain barrier to allow transport of anti-cancer
agents to the brain for use in the entire human body.
The blood-brain barrier is a transvascularpermeability barrier
which is a result of the interendothelial tight junctions
formed by cerebrovascular endothelial cells of brain capillaries
and arterioles in brain tissues. It is known that few methodologies
and techniques allow transport of anti-cancer agents to selectively
open the blood-brain barrier in humans while leaving the barrier
in normal brain tissue intact. This has been a significant
issue in utilizing anti-tumor agents, such as nitric oxide
(NO) in the treatment of human cancers.
NO is known to play a significant role in anti-tumor activity
in humans and an important role in the regulation of the blood-brain
barrier. It is evidenced that NO can activate the calcium-activated
potassium channel (Kca) by both cGMP-dependent and independent
mechanisms. In order for this to occur, L-arginine, the sole
NO molecule in the human body, must be allowed to cross the
blood-brain barrier uninhibited so NO can be transported to
specific sites for anti-tumor activity. This delicate mechanism
has remained a mystery in medical science until recently.
Following a twenty-year development period, a Patent has been
issued to Dr. Ann de Wees Allen for an L-arginine compound
that allows transport of L-arginine across the blood-brain
barrier for production of growth hormone (GH) anti-aging hormone,
and nitric oxide (NO).
Dr. Allen's L-arginine formula utilizes a low glycemic base
of Trutina Dulcem and non-competing amino acids developed
under proprietary conditions. The specific formula prevents
brain-hypoglycemia from blunting NO and GH produced via oral
ingestion of large amounts of elemental L-arginine, and allows
production of NO and GH without any side effects, thus allowing
complete blood-brain barrier cross over. L-arginine formulas
that contain sucrose, sugars, maltodextrins,
and other sweetening agents have been shown in clinical studies
to blunt nitric oxide (NO) and GH.
Serious side effects related to excess NO and GH are evidenced
in many L-arginine, nitric oxide, and growth hormone formulas
currently on the market. When asked to comment on these "rogue
products," Dr. Allen stated, "It's quite disturbing
to see L-arginine and nitric oxide products popping into the
market that have virtually no history of safe use and no science
related to the development of the product." "You
cannot simply take L-arginine and produce a valid product.
It takes years of research."
Dr. Ann de Wees Allen's patents have been named "Breakthrough
Product of the Year" by Success magazine and have been
featured on the front page of the Wall Street Journal. She
is named in the Who's Who of Inventors and Diabetes Educators.
Her patents, CV, and arginine research projects may be seen